Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


2 Blood
1 Bone Marrow Transplant
1 Br J Haematol
1 Cancer
3 Eur J Haematol
3 Haematologica
2 Int J Cancer
2 J Clin Oncol
3 Leuk Lymphoma
3 Leukemia
2 N Engl J Med

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles


  1. YAMAGUCHI M, Suzuki R, Oguchi M
    Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Blood. 2018 Mar 30. pii: blood-2017-12-791418. doi: 10.1182/blood-2017-12-791418
    PubMed     Text format     Abstract available

  2. BATTISTELLO E, Katanayeva N, Dheilly E, Tavernari D, et al
    Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
    Blood. 2018 Mar 22. pii: blood-2017-10-809210. doi: 10.1182/blood-2017-10-809210
    PubMed     Text format     Abstract available

    Bone Marrow Transplant

  3. NAITHANI R, Dayal N, Pathak S, Rai R, et al
    Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma.
    Bone Marrow Transplant. 2018 Mar 29. pii: 10.1038/s41409-018-0174.
    PubMed     Text format    

    Br J Haematol

  4. NGUYEN KA, Su C, Bai HX, Zhang Z, et al
    Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database.
    Br J Haematol. 2018 Mar 30. doi: 10.1111/bjh.15145.
    PubMed     Text format     Abstract available


  5. GREENWELL IB, Staton AD, Lee MJ, Switchenko JM, et al
    Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31328.
    PubMed     Text format     Abstract available

    Eur J Haematol

  6. LAKSHMAIAH KC, Asati V, Babu KG, Lokanath D, et al
    Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2018 Mar 22. doi: 10.1111/ejh.13068.
    PubMed     Text format     Abstract available

  7. KRIEGSMANN K, Rieger M, Schwarzbich MA, Sitter S, et al
    Outcome after high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2018 Mar 25. doi: 10.1111/ejh.13064.
    PubMed     Text format     Abstract available

  8. CHENG CL, Liu JH, Chou SC, Yao M, et al
    Retrospective analysis of front line treatment efficacy in elderly patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13069.
    PubMed     Text format     Abstract available


  9. BELLEI M, Foss FM, Shustov AR, Horwitz SM, et al
    The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.
    Haematologica. 2018 Mar 29. pii: haematol.2017.186577.
    PubMed     Text format     Abstract available

    CD83 in Hodgkin lymphoma.
    Haematologica. 2018;103:561-562.
    PubMed     Text format    

  11. HORN H, Kohler C, Witzig R, Kreuz M, et al
    Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.
    Haematologica. 2018 Mar 22. pii: haematol.2017.181024.
    PubMed     Text format     Abstract available

    Int J Cancer

  12. BASSIG BA, Willhauck-Fleckenstein M, Shu XO, Koh WP, et al
    Serologic markers of viral infection and risk of non-Hodgkin lymphoma: A pooled study of three prospective cohorts in China and Singapore.
    Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31385.
    PubMed     Text format     Abstract available

  13. CALIP GS, Patel PR, Adimadhyam S, Xing S, et al
    Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions.
    Int J Cancer. 2018 Mar 30. doi: 10.1002/ijc.31407.
    PubMed     Text format     Abstract available

    J Clin Oncol

  14. CHESON BD, Chua N, Mayer J, Dueck G, et al
    Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    J Clin Oncol. 2018 Mar 27:JCO2017763656. doi: 10.1200/JCO.2017.76.3656.
    PubMed     Text format     Abstract available

  15. ARMAND P, Engert A, Younes A, Fanale M, et al
    Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    J Clin Oncol. 2018 Mar 27:JCO2017760793. doi: 10.1200/JCO.2017.76.0793.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  16. DHOLARIA BR, Hammond WA, Roy V, Sher T, et al
    Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience.
    Leuk Lymphoma. 2018 Mar 23:1-4. doi: 10.1080/10428194.2018.1452220.
    PubMed     Text format    

  17. ZHANG PP, Ding DZ, Shi B, Zhang SQ, et al
    Expression of TRIM28 correlates with proliferation and Bortezomib-induced apoptosis in B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452207.
    PubMed     Text format     Abstract available

  18. WIGHT JC, Hawkes EA, Berlangieri SU, Khor R, et al
    An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
    Leuk Lymphoma. 2018 Mar 23:1-3. doi: 10.1080/10428194.2018.1452217.
    PubMed     Text format    


  19. SCHLEUSSNER N, Merkel O, Costanza M, Liang HC, et al
    The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.
    Leukemia. 2018 Mar 28. pii: 10.1038/s41375-018-0045.
    PubMed     Text format     Abstract available

  20. RULE S, Jurczak W, Jerkeman M, Rusconi C, et al
    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0023.
    PubMed     Text format    

  21. ARAF S, Wang J, Korfi K, Pangault C, et al
    Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
    Leukemia. 2018 Feb 8. pii: 10.1038/s41375-018-0043.
    PubMed     Text format    

    N Engl J Med

  22. TAM CS, Anderson MA, Pott C, Agarwal R, et al
    Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    N Engl J Med. 2018;378:1211-1223.
    PubMed     Text format     Abstract available

  23. YARCHOAN R, Uldrick TS
    HIV-Associated Cancers and Related Diseases.
    N Engl J Med. 2018;378:1029-1041.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.